HIF1A and postmenopausal osteoporosis: This system can activate the HIF‐1α signaling pathway, mitigate bone resorption, and alleviate osteoporotic symptoms, thus offering a novel therapeutic strategy for preventing postmenopausal osteoporosis.[24] However, chemical hypoxia agents elevate HIF‐1α/2α levels in a time‐ and dose‐dependent manner and exhibit cytotoxic effects at high concentrations, thus limiting their in vivo applications.[25] Physical hypoxia offers superior biosafety, but directly reducing oxygen concentrations in the microenvironment via physical interventions remains a significant challenge.